Webcasts - Pharmaceutical Executive

Webcasts

LIVE WEBCASTS

Clinical Study Data Integration - the Art and the Promise
Wednesday, July 8, 2009 at 11:00 AM EST

In the life sciences industry, the process of clinical development requires that patient data collected from multiple sources be merged and combined for the purpose of understanding the safety and efficacy of a compound. Quick and accurate access to this combined data can:

Inform management decisions to alter, accelerate, or cancel the development of a particular compound and thus increase profits
Deliver data for formal structured analysis to accelerate regulatory submissions
Minimize the risk of introducing an unsafe compound to the market

Sponsor:
Oracle Health Sciences

ON-DEMANDS NOW AVAILABLE FOR REPLAY

The Unvarnished Truth about Comparative Effectiveness
Recorded on: June 25, 2009

The mere mention of the term "comparative effectiveness" evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. President Obama has called for a national agency for comparative effectiveness. Congress introduced a bill in summer 2008 that would have set the stage for comparative effectiveness at a federal level. No one doubts that comparative effectiveness is coming to healthcare - but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare? More

Register Free at www.pharmexec.com/effectiveness

Sponsor:
AmerisourceBergen Specialty Group

Data driven laboratory asset management programs - Unlock unknown capital and drive efficiency while improving quality and scientist experience
Recorded on: June 17, 2009

With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify processes and increase productivity across all sites and functions. More companies are starting to focus on their laboratory assets, how these are maintained, how validation is carried out, how downtime affects their operations and scientists' productivity, how those assets are being utilized and whether they have over/under capacity. Our lifecycle asset management programs go well beyond asset maintenance and provide you with a future proof solution that will improve scientist productivity, support capital investment strategies, help drive efficiency through multiple functions without compromising quality or scientist experience.

Register Free at www.pharmexec.com/datadriven

Sponsor:
GE Healthcare

Video: Early Phase Strategies to Increase the Success of Later Phase Trials
Recorded on: May 27, 2009

Many pharmaceutical and biotech organizations miss the opportunity to develop Early Phase strategies to transition to Later Phase success. For example, 41% of all New Drug Applications (NDAs) fail due to insufficient information on the optimal dose. By including "real patient" populations in Phase I/IIa studies, these organizations could: Obtain data from the type of patients who will eventually be used in Phase III trials. Devise population modeling and simulation techniques to eliminate the effects of co-variates and improve Proof-of-Concept.

Register Free at www.pharmexec.com/earlyphase

Sponsor:
Quintiles

Wanted: A Single Version of the Truth for Your Customer Data
Recorded on: May 20, 2009

The Life Sciences industry faces many challenges as they close out the first decade of the new millennium. Well documented as one of the most highly regulated Industries, companies are faced with maintaining compliance while operating in an era of corporate downsizing. The solution is rooted in the often underestimated area of master data management. Join us for this free live webcast, featuring a panel of industry experts who will share practical insights to help you improve your business processes starting from their very foundation.

Register Free at www.pharmexec.com/truth

Sponsor:
Cegedim Dendrite

Video: Transforming Sales & Marketing Given Today's Pharma Realities: A New Model for Success
Recorded on: May 12, 2009

The world’s top pharmaceutical markets have hit maturity. Growth has slowed, especially in primary care, and companies are shifting to a specialty focus. Have your sales and marketing strategies adapted to this new reality? Over the past decade, and especially over the last three years, the largest pharma markets have been utterly transformed. Tried and true strategies can no longer keep up. Across the industry, executives are asking:
Exactly how much are companies overspending on promotion or misdirecting budgets to unproductive activities?
What are the implications of this as they look for way to further cut costs and reduce infrastructure?
Which commercial model will make the most efficient use of resources given rising consumer and payer demand, increased competition/genericization and a growing specialty product focus?

Register Free at www.pharmexec.com/commercialmodels

Sponsor:
IMS Health

Understanding the Complexities of State Licensing and VAWD
Recorded on: April 21, 2009

The changing environment surrounding the requirements for state licensure of manufacturers and wholesalers can be difficult to understand. Knowing the importance and your responsibility surrounding VAWD and the definitions around "wholesaler" and "manufacturer" are unclear to many companies. Join us to discuss industry challenges, and hear from experts who have successfully managed the complexities and dynamics of state licensure. Hear what is being done as an industry to understand and monitor the complex database of rules and regulations that define "wholesale distribution". And learn about cost effective solutions to ensure compliance with state licensing requirements and how to best stay current with future legislative changes in this complex environment.

Register Free at www.pharmexec.com/VAWD

Sponsor:
Cegedim Dendrite

Revolutionizing KOL Relationship Management for Maximum Impact
Recorded on: February 24, 2009

2009 promises to bring increased regulatory and financial scrutiny to the life sciences industry as new regulations and public health policy reforms loom on the horizon. This will force pharmaceutical companies to change the ways they interact with key physicians and opinion leaders in an effort to increase transparency and ethical outcomes. To address these issues, a forward-thinking Key Opinion Leader (KOL) Management strategy is required to ensure regulatory compliance that enables knowledge sharing, communication, and visibility. As a result, your team will develop trusted, credible scientific peer relationships between your company, your MSLs and thought leaders. click here.

Register Free at www.pharmexec.com/KOL

Sponsor:
Cegedim Dendrite

No More Tiers! A New Approach for Evaluating Formulary Contracts
Recorded on: February 11, 2009

Since the adoption of three tier benefit designs by insurers and PBMs in the early 1990’s, Pharmaceutical Executives have argued about the value of contracting for preferred (Tier 2) status for their brands. Managed care executives within Pharma have been measured primarily in terms of the percent of lives having Tier 2 access. Brands and sales forces have blamed a lack of Tier 2 access for not achieving their uptake goals. But what is that Quality of Access for Tier 2, how has it changed over time and how much does it actually differ from Tier 3? Where does it differ significantly? Does it matter? Does it matter enough to pay the rebates expected by Managed Care plans? click here.

Register Free at www.pharmexec.com/tiers

Sponsor:
Amundsen Group and Wolters Kluwer Health

Using Patient Adherence programs to Prove the Value of your Brands for today´s Payor Marketplace
Recorded on: January 30, 2009

Pharma is facing a new reality: As never before, key customers—from prescription drug plans to government to large medical practices—are demanding data on patient outcomes. As pharma companies scramble to meet these new expectations many are ignoring a powerful data source that they may already have developed: their own patient adherence programs. Patient adherence programs are a vital part of pharma companies’ strategy today, and their value is all the greater when they can be used to generate data that supports the value of brands. For hands-on, up-to-date insight on how to coordinate these two goals for the benefit of patients and brand alike, we urge you to attend this new, live webcast, featuring industry experts in both compliance and marketing. click here.

Register Free at www.pharmexec.com/payormarketplace

Sponsor:
Innovex

Maximizing Efficiencies in the Pharmaceutical Laboratory, Part 2: Addressing Productivity and Time-to-Market through Analytical Technology Choices
Recorded on: October 8, 2008

Today, the mandate for drug manufacturers is to improve efficiency and productivity-and with ever-more competition, to do so on an increasingly tighter timeline. The greatest opportunity to do more with less (and faster) is in the laboratory, where new strategies and new technology can reduce operating costs, maximize asset utilization, and improve drug's time to market. This Webinar series focuses on translating new analytical technology into major business advantages. Part I focused on how to improve the use of existing MS instrumentation. In Part II, listeners will learn how they can rethink their strategy to increase the quality of laboratory output and improve productivity to get their drug to market first. These factors have always been crucial for generics manufacturers, where a missed deadline can mean forfeiting first-to-file exclusivity. But in the branded, innovative industry, these are becoming more critical as well in determining a drug's commercial success and position in the market. click here.

Register Free at www.pharmexec.com/atc

Sponsor:
WATERS

Video Webcast - Playing to Win in the Dynamic Market
Recorded on: October 1, 2008

New research from IMS Health confirms: In chronic retail markets, 85 to 90 percent of prescriptions form a static market comprised of refills and repeat prescriptions that is virtually invulnerable to traditional promotion. Pharmaceutical companies have the opportunity to influence 10 to 15 percent of prescriptions the segments containing new therapy starts, add-on therapy and product switches. This dynamic market is critical to any pharmaceutical company´s profitable growth, but is difficult to identify using common metrics, creating inefficient resource allocation and ultimately sub-optimizing field force performance. click here.

Register Free at www.pharmexec.com/dynamic

Sponsor:
IMS

Complying with State Reporting in a Rapidly Changing Environment
Recorded on: July 23, 2008

Regulatory compliance is a tough job and it´s becoming that much tougher as individual states jump into the game with their own laws governing expenditures on pharma sales promotion, marketing and advertising. Not only do these laws require companies to track data in new ways and generate an array of complex new reports; they also force pharma companies to alter their processes, systems, and personnel training in order to avoid the fines and negative publicity that accompany noncompliance. That´s more, state-level regulations have introduced a whole new level of instability into pharmaceutical regulation: five of the current seven states with enacted legislation announced revisions to their reporting requirements in the last 12 months. click here.

Register Free at www.pharmexec.com/statereporting

Sponsor:
Cegedim Dendrite

Account Management... New Strategy for Pharma Sales Organizations
Recorded on: September 16, 2008

Perhaps no part of the pharmaceutical industry is experiencing as much change as the sales organization. As payer dynamics evolve; government, managed care, and consumer out-of pocket spending increase; and specialty drugs and high-priced biologics grow in importance, pharma sales organizations are racing to adapt to the new model. One key area for change is a new level of focus on payers, institutional customers, and of course Key Account Management. KAM teams have long been a valuable tool for pharma, but their growing importance presents major challenges in organizational structure, coordination, visibility, and technological support. click here.

Register Free at www.pharmexec.com/pso

Sponsor:
Cegedim Dendrite

Maximizing Efficiencies in the Pharmaceutical Laboratory, Part 1: Better Asset Utilization of Existing MS Instrumentation
Recorded on: September 11, 2008

In this discussion, we demonstrate how to translate the deployment of a new analytical technology into major business advantages. The pharmaceutical industry is increasingly focused on the careful management of expenses and resource utilization. Many companies to date have realized that by optimizing laboratory operations, they provide an opportunity to greatly enhance overall corporate productivity. The best managers know that the analytical laboratory is a strategic asset and that by making the right choice in LC technology today, they can extend the useful life and performance of high-cost existing mass spectrometer investments. click here.

Register Free at www.pharmexec.com/efficiencies

Sponsor:
WATERS

A Better Way to Conduct Alliance Management
Recorded on: July 31, 2008

Look at any pharmaceutical and biotech company today, and chances are good that it stands at the center of an intricate network of alliances and partnerships, license agreements, research partnerships, co-marketing deals, and strategic relationships with research and manufacturing partners. At top companies, alliance management teams are mastering the skills and infrastructure needed to keep partnerships productive. What have they learned? Find out in an exclusive webcast that brings together alliance managers to share their experiences in building and maintaining successful partnerships. click here.

Replay Free at www.pharmexec.com/AllianceManagement

Sponsor:
IntraLinks

Emerging, Provider-facing Technologies: How They Impact Prescribing Decisions and Patient Care
Recorded on: July 23, 2008

More than any other specialty, oncology faces tremendous scrutiny and pressure to reduce the cost of care. Public and private payers, as well as oncology practices themselves, seek new methods for decision support and quality measurement. New technology solutions are coming to market to meet these needs but what impact will they have on product use and patient care? Join us for an in-depth Webcast that provides insight on how these new technologies may have a profound effect on the future of oncology relative to clinical decisions, benchmarking, quality control, outcomes analysis and practice efficiencies. click here.

Replay Free at www.pharmexec.com/oncologytechnology

Sponsor:
ION